RxDoctor Payments Data

Ema Avdagic

Ophthalmology · Chicago, ILNPI 1497287148

Payments from drug & device makers

$17,279in general payments, 2019–2025

Across 113 payments — averaging $152.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$8K
  • Glaukos Corporation$7K
  • Alcon$659
  • AbbVie$542
  • NEW World Medical,inc.$388
  • Carl Zeiss Meditec, Inc.$146
  • plus $649 from 9 others

What the payments were for

  • Consulting fees$3,98023%
  • Speaking & faculty fees$7,32842%
  • Travel & lodging$2,07212%
  • Food & beverage$3,89823%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,279 in reported general payments places this provider in the 85th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$272,750
Medicare patients
416
Services billed
1,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate389$194,324
RocklatanNetarsudil Mesylat/Latanoprost284$157,088
LumiganBimatoprost160$84,159
Prednisolone Acetate1,201$38,055
CombiganBrimonidine Tartrate/Timolol72$33,117
Latanoprost2,213$32,912
Brimonidine Tartrate1,229$25,191
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,265$24,920
VyzultaLatanoprostene Bunod49$23,464
Travoprost101$22,511
Alphagan PBrimonidine Tartrate32$17,416
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol75$15,543
Ketorolac Tromethamine756$12,330
Timolol Maleate440$9,812
SimbrinzaBrinzolamide/Brimonidine Tart35$9,754

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P, Restasis$542$143,759276 claims
Bausch & Lomb Americas Inc.Vyzulta$41$23,46449 claims
AlconSimbrinza$659$9,75435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →